Company Analysis
Sign in

Cyclerion Therapeutics, Inc. (CYCN)

Nasdaq: CYCN · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2018
Full chart Alerts Compare
Grade4.9
◀ Past 4.2● Present 5.3▶ Future 5.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$2.1M+3.7%
Net income-$3.5M-15.4%
Earnings per share$-1.11+8.3%
Operating cash flow-$3.3M+23.5%
Cash$3.2M+0.2%
Debtn/a
Shareholders’ equity$9.1M+2.7%
Shares, diluted3,181,000+26.3%
Return on equity-38.8%
The recordfrom its filings
Filings in 202658
Newest filingNov 10 · SCHEDULE 13G
Annual reportMar 30, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted24
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $1.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 15, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton CYCN · research, not advice